8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2017)

Filed July 20, 2017For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on July 20, 2017, to report its second-quarter 2017 financial results. The filing primarily announces the results of operations for the quarter, which are detailed in a press release furnished as Exhibit 99.1. Investors should note that Abbott uses non-GAAP financial measures, which exclude items such as acquisition and restructuring expenses, cost reduction initiatives, gains from business sales, currency devaluation, and tax resolutions, to provide a clearer view of ongoing operational performance. While these non-GAAP measures are used by management for internal assessment and offer investors a way to evaluate underlying business performance, they should be considered alongside GAAP measures. The primary purpose of this 8-K is to make these second-quarter results publicly available, with the detailed financial figures and management's discussion contained within the referenced press release.

Key Highlights

  • 1Abbott Laboratories announced its second-quarter 2017 financial results via an 8-K filing on July 20, 2017.
  • 2The report includes a press release (Exhibit 99.1) detailing the Q2 2017 financial performance.
  • 3Abbott utilizes non-GAAP financial measures to present earnings, excluding specified items to highlight ongoing operational performance.
  • 4Excluded items include acquisition/restructuring costs, cost reduction charges, gains on business sales, Venezuela devaluation expenses, and tax resolutions.
  • 5Intangible amortization expense is also excluded in non-GAAP reporting for enhanced visibility.
  • 6Management believes these non-GAAP measures offer valuable insights into the company's underlying business performance.
  • 7Investors are advised to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financial measures.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the second quarter of 2017 and to furnish the related press release as an exhibit.

Abbott uses non-GAAP financial measures to provide a clearer view of its ongoing operational performance. These measures exclude certain items that are unusual or unpredictable, such as expenses related to acquisitions, restructuring, cost reduction initiatives, gains from asset sales, currency devaluations, and tax settlements. Management uses these measures internally and believes they offer investors a better way to evaluate the core business performance.

The detailed financial results for the second quarter of 2017 are provided in the press release that is furnished as Exhibit 99.1 to this 8-K filing.

No, investors are cautioned by Abbott to consider the non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should review both GAAP and non-GAAP figures for a complete understanding.